壮药扶正复方联合EGFR-TKIs治疗晚期EGFR敏感型突变非小细胞肺癌的疗效及对患者生活质量的影响  

Efficacy of Zhuangyaofuzheng compound combined with EGFR-TKIS in the treatment of advanced EGFR-sensitive mutation non-small cell lung cancer and its impact on patients′quality of life

作　　者：莫娟梅 张顺荣 于起涛[2] 宁瑞玲[2] 李琼谦 甘芷川 欧桂 MO Juanmei;ZHANG Shunrong;YU Qitao(Guangxi International Zhuang Medicine Hospital,Guangxi Zhuang Autonomous Region,Nanning 530000,China;不详)

机构地区：[1]广西国际壮医医院,南宁市530000 [2]广西医科大学附属肿瘤医院,南宁市530000

出　　处：《临床合理用药杂志》2021年第31期17-20,24,共5页Chinese Journal of Clinical Rational Drug Use

基　　金：广西壮族自治区中医药管理局自筹经费科研课题(No:GZZC2020133);广西中医药大学2019~2021年广西一流学科建设开放课题(No:2019XK065);广西国际壮医医院资助科研课题(No:2019005)。

摘　　要：目的观察壮药扶正复方联合表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)治疗晚期EGFR敏感型突变非小细胞肺癌(NSCLC)的效果及对患者生活质量的影响。方法将2018年9月-2019年7月广西国际壮医医院肿瘤科收治且符合纳入标准的NSCLC患者150例纳入研究,通过随机数字表法分为联合组和单一组各75例,联合组采用壮药扶正复方联合EGFR-TKIs治疗,单一组采用EGFR-TKIs治疗,比较2组患者治疗效果,治疗前后免疫指标、中医证候评分、生活质量评分、无进展生存期(PFS)及药物不良反应。结果2组患者客观缓解率(ORR)比较差异无统计学意义(57.33%vs.53.33%,χ^(2)=0.243,P=0.622);联合组患者疾病控制率(DCR)为88.00%,高于单一组的73.33%,差异有统计学意义(χ^(2)=5.172,P=0.023)。2组患者治疗4周后CD3+、CD4+及CD8+水平均高于治疗前,且联合组高于单一组,差异均有统计学意义(P<0.01)。2组患者治疗4周后中医证候评分均低于治疗前,总体健康状况、躯体功能、角色功能、情绪功能、认知功能及社会功能评分均高于治疗前,且联合组降低/升高幅度大于单一组,差异均有统计学意义(P<0.01)。随访15个月,联合组患者PFS长于单一组,差异有统计学意义(P<0.01)。联合组患者治疗期间各项不良反应发生率均低于单一组,差异均有统计学意义(P<0.05)。结论壮药扶正复方联合EGFR-TKIs治疗晚期EGFR敏感型突变NSCLC的效果较好,可提高患者免疫功能及生活质量,且可减少不良反应,具有重要的推广价值。Objective To observe the effect of Zhuangyaofuzheng compound combined with epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-Tkis)in the treatment of advanced EGFR-sensitive mutation non-small cell lung cancer(NSCLC)and the impact on the quality of life of patients.Methods A total of 150 NSCLC patients admitted to the Department of Oncology,Guangxi International Zhuang Medicine Hospital from September 2018 to July 2019 who met the inclusion criteria were included in the study.They were divided into the combined group and the single group by random number table method,with 75 patients in each group.The combined group was treated with Zhuangyaofuzheng compound combined with EGFR-TKIs,and the single group was treated with EGFR-TKIS.The treatment effect,progression-free survival(PFS),overall survival(OS),immune indexes,TCM syndrome scores,quality of life scores before and after treatment and adverse drug reactions were compared between two groups.Results There was no significant difference in ORR between the two groups(57.33%vs.53.33%,χ^(2)=0.243,P=0.622).The DCR of the combined group was 88.00%,which was higher than 73.33%of the single group,the difference was statistically significant(χ^(2)=5.172,P=0.023).After 4 weeks of treatment,the levels of CD3+,CD4+and CD8+in two groups were higher than before treatment,and the combined group was higher than the single group,the difference were statistically significant(P<0.01).After 4 weeks of treatment,the TCM syndrome scores of two groups were lower than before treatment,and the overall health status,physical function,role function,emotional function,cognitive function and social function scores were higher than before treatment,and the decrease/increase range of the combined group was greater than that of the single group,the difference were statistically significant(P<0.01).Followed up for 15 months,the PFS of combined group were longer than that of single group,the difference was statistically significant(P<0.01).The incidence of adverse reactions in th

关 键 词：非小细胞肺癌 晚期 EGFR敏感型突变 壮药扶正复方 表皮生长因子受体酪氨酸酶抑制剂 生活质量 免疫指标 

分 类 号：R734.2[医药卫生—肿瘤]